[1] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2016[J]. CA: A Cancer Journal for Clinicians, 2016, 66(1): 7-30.
[2] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2019[J]. CA: A Cancer Journal for Clinicians, 2019, 69(1): 7-34.
[3] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2020[J]. CA: A Cancer Journal for Clinicians, 2020, 70(1): 7-30.
[4] Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics, 2021[J]. CA: A Cancer Journal for Clinicians, 2021, 71(1): 7-33.
[5] Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics, 2022[J]. CA: A Cancer Journal for Clinicians, 2022, 72(1): 7-33.
[6] Siegel R L, Miller K D, Wagle N S, et al. Cancer statistics, 2023[J]. CA: A Cancer Journal for Clinicians, 2023, 73(1): 17-48.
[7] Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat database: Incidence-SEER research data with delay-adjustment, 8 registries, malignant only(1975—2019), based on the November 2021 submission[EB/OL]. [2023-06-23]. https://seer.cancer.gov/data.
[8] Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat database: Mortality-All causes of death, total U. S. (1969—2020) (with underlying mortality data provided by the National Center for Health Statistics)[EB/OL]. [2023-06-23]. http://seer.cancer.gov/data.
[9] Wingo P A, Cardinez C J, Landis S H, et al. Long-term trends in cancer mortality in the United States, 1930—1998[J]. Cancer, 2003, 97(Suppl 12): 3133-3275.
[10] Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) incidence data-cancer in North America (CiNA) analytic file, 1995—2019, with race/ethnicity, custom file with county, american cancer society facts & figures projection project (which includes data from the Centers for Disease Control and Prevention's National Program of Cancer Registries, the Canadian Counsel of Cancer Registry's Provincial and Territorial Registries, and the National Cancer Institute's SEER Registries), certified by the NAACCR as meeting high-quality incidence data standards for the specified time periods, submitted December 2021[EB/OL]. [2023-06-23]. https://seer.cancer.gov/data-software/documentation/seerstat.
[11] World Health Organization. International classification of diseases for oncology. Third edition[R]. Geneva: WHO, 2000.
[12] Steliarova-Foucher E, Colombet M, Ries L A G, et al. International incidence of childhood cancer, 2001-10: A population-based registry study[J]. Lancet Oncology, 2017, 18(6): 719-731.
[13] Steliarova-Foucher E, Stiller C, Lacour B, et al. International classification of childhood cancer, third edition[J]. Cancer, 2005, 103(7): 1457-1467.
[14] World Health Organization. International statistical classification of diseases and related health problems, tenth revision, volumes I-III[R]. Geneva: WHO, 2011.
[15] Doll R, Cook P. Summarizing indices for comparison of cancer incidence data[J]. International Journal of Cancer, 1967, 2(3): 269-279.
[16] Surveillance Research Program, National Cancer Institute. SEER*Stat software, version 8.4.0[EB/OL]. [2023-06-23]. https://seer.cancer.gov/seerstat.
[17] Statistical Research and Applications Branch, National Cancer Institute. Joinpoint regression program, version 4.9.1.0[EB/OL]. [2023-06-23]. https://surveillance. cancer.gov/joinpoint.
[18] Clegg L X, Feuer E J, Midthune D N, et al. Impact of reporting delay and reporting error on cancer incidence rates and trends[J]. Journal of the National Cancer Institute, 2002, 94(20): 1537-1545.
[19] Miller K D, Siegel R L, Liu B, et al. Updated methodology for projecting U.S.- and state-level cancer counts for the current calendar year: Part II: Evaluation of incidence and mortality projection methods[J]. Cancer Epidemiology, Biomarkers & Prevention, 2021, 30(11): 1993-2000.
[20] Liu B, Zhu L, Zou J, et al. Updated methodology for projecting U.S.- and state-level cancer counts for the current calendar year: Part I: Spatio-temporal modeling for cancer incidence[J]. Cancer Epidemiology, Biomarkers & Prevention, 2021, 30(9): 1620-1626.
[21] Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. Journal of the National Cancer Center, 2022, 2(1): 1-9.
[22] Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567.
[23] 尹周一, 王梦圆, 游伟程, 等 . 2022 美国癌症统计报告解读及中美癌症流行情况对比[J]. 肿瘤综合治疗电子杂志, 2022, 8(2): 54-63.
[24] Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat database: Incidence-SEER research data, 9 registries (1975—2018), based on the November 2020 submission[EB/OL]. [2023-06-23]. http://seer.cancer.gov/data.
[25] Surveillance, Epidemiology and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) incidence data-cancer in North America (CiNA) research data, 2015—2019, delay-adjusted factors-american cancer society facts & figures (which includes data from the Centers for Disease Control and Prevention's National Program of Cancer Registries, the Canadian Council of Cancer Registry's Provincial and Territorial Registries, and the National Cancer Institute's SEER Registries), certified by the NAACCR, submitted December 2021[EB/OL].[2023-06-23]. http://seer.cancer.gov/data/.
[26] Surveillance Research Program, Statistical Methodology and Applications Branch, National Cancer Institute. DevCan: Probability of developing or dying of cancer software, version 6.8.0[EB/OL]. [2023-06-23]. https://surveillance.cancer.gov/devcan.
[27] Tsodikov A, Gulati R, Heijnsdijk E A M, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials[J]. Annals of Internal Medicine, 2017, 167(7): 449-455.
[28] Yabroff K R, Wu X C, Negoita S, et al. Association of the COVID-19 pandemic with patterns of statewide cancer services[J]. Journal of the National Cancer Institute, 2022, 114(6): 907-909.
[29] Pfeiffer R M, Webb-Vargas Y, Wheeler W, et al. Proportion of U. S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions[J]. Cancer Epidemiology, Biomarkers & Prevention, 2018, 27(10): 1214-1222.
[30] Henley S J, Thomas C C, Sharapova S R, et al. Vital signs: Disparities in tobacco-related cancer incidence and mortality-United States, 2004—2013[J]. Morbidity and Mortality Weekly Report, 2016, 65(44): 1212-1218.
[31] Bibbins-Domingo K, Grossman D C, Curry S J, et al. Screening for thyroid cancer: US preventive services task force recommendation statement[J]. The Journal of the American Medical Association, 2017, 317(18): 1882-1887.
[32] Haugen B R. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: What is new and what has changed?[J]. Cancer, 2017, 123(3): 372-381.
[33] Ugai T, Sasamoto N, Lee H Y, et al. Is early-onset cancer an emerging global epidemic? Current evidence and future implications[J]. Nature Reviews Clinical Oncology, 2022, 19(10): 656-673.
[34] Menvielle G, Kulhánová I, Bryère J, et al. Tobacco-attributable burden of cancer according to socioeconomic position in France[J]. International Journal of Cancer, 2018, 143(3): 478-485.
[35] Zhang J, Ou J X, Bai C X. Tobacco smoking in China: Prevalence, disease burden, challenges and future strategies[J]. Respirology, 2011, 16(8): 1165-1172.
[36] Wang L, Zhou B, Zhao Z, et al. Body-mass index and obesity in urban and rural China: Findings from consecutive nationally representative surveys during 2004-18[J]. Lancet, 2021, 398(10294): 53-63.
[37] Chen W, Xia C, Zheng R, et al. Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: A comparative risk assessment[J]. Lancet Glob Health, 2019, 7(2): 257-269.
[38] Li W Q, Qin X X, Li Z X, et al. Beneficial effects of endoscopic screening on gastric cancer and optimal screening interval: A population-based study[J]. Endoscopy, 2022, 54(9): 848-858.
[39] Li W Q, Zhang J Y, Ma J L, et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: Follow-up of a randomized intervention trial[J]. British Medical Journal, 2019, 366: l5016.
[40] Zeng H, Ran X, An L, et al. Disparities in stage at diagnosis for five common cancers in China: A multicentre, hospital-based, observational study[J]. Lancet Public Health, 2021, 6(12): 877-887.
[41] 魏文强, 沈洪兵 . 中国癌症防控历史、现状与展望[J].中华疾病控制杂志, 2019, 23(10): 1165-1168.
[42] 滕熠, 曹毛毛, 陈万青 . 中国癌症筛查的发展、现状与挑战[J]. 中国肿瘤, 2022, 31(7): 481-487.
[43] 曹毛毛, 陈万青 . 癌症筛查和早诊早治——实现全民健康助力全面小康[J]. 中国肿瘤, 2020, 29(9): 641-643.
[44] Xu H, Li W. Early detection of gastric cancer in China: Progress and opportunities[J]. Cancer Biology & Medicine, 2022, 19(12): 1622-1628.
[45] 刘宗超, 李哲轩, 张阳, 等 . 2020 全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-14.
